Aarti Pharmalabs Limited has commissioned a state-of-the-art manufacturing block at its Tarapur Unit 5 facility in MIDC Tarapur, Maharashtra, marking a significant expansion of its specialty pharmaceutical manufacturing capabilities.
The newly operational block adds 3,600 tonnes per annum (TPA) of Xanthine derivatives production capacity, increasing the company’s total installed capacity to 9,600 TPA. With this expansion, Aarti Pharmalabs strengthens its position among the top three global manufacturers of Xanthine derivatives.
Project Highlights:
🔹 Location: Unit 5, MIDC Tarapur, Maharashtra
🔹 Additional Capacity: 3,600 TPA
🔹 Total Installed Capacity: 9,600 TPA
🔹 Product: Xanthine Derivatives
🔹 Status: Commissioned; trial production underway
🔹 Operations Ramp-up: Planned over the coming quarters
The new manufacturing block has secured all required statutory approvals and regulatory clearances and is designed to meet the growing global demand for pharmaceutical and nutraceutical ingredients while maintaining high standards of quality, compliance and operational excellence.
Commenting on the milestone, Rashesh Gogri, Chairman, Aarti Pharmalabs Limited, said the investment significantly enhances the company’s production capabilities and reinforces its long-term commitment to supporting customers across global markets through expanded capacity and manufacturing excellence.
The expansion is expected to improve supply reliability, increase production flexibility and strengthen Aarti Pharmalabs’ position in high-value specialty pharmaceutical ingredients. The company continues to expand its capabilities across CDMO, CMO, generic APIs, intermediates, HPAPIs, oncology products, and specialty pharmaceutical ingredients for regulated global markets.
#AartiPharmalabs #Pharmaceuticals #Manufacturing #Expansion #Tarapur #Maharashtra #API #CDMO #CMO #SpecialtyChemicals #PharmaIndustry #IndustrialGrowth #MakeInIndia #ProjectIndustrialBuzz